 |
|
| node: | Hydroxychloroquine and azithromycin as a treatment of COVID-19 |
| template: | 4 |
| parent: | CoVid-19 pharmaceuticals |
| owner: | imnot |
| viewed by: | |
| created: | 18.03.2020 - 17:32:13 |
| updated: | 20.03.2020 - 07:50:27 |
|
cwbe coordinatez: 101 8333809 8837211 8723038 8726526 ABSOLUT KYBERIA |
| permissions | |
| you: | r, |
| system: | public |
| net: | yes |
total descendants::15
total children::6
3 ❤️
French Confirmed COVID-19 patients were included in a single arm protocol from early
March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in
nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical
presentation, azithromycin was added to the treatment. Untreated patients from another center
and cases refusing the protocol were included as negative controls. Presence and absence of
virus at Day6-post inclusion was considered the end point.
Results
Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight
had lower respiratory tract infection symptoms.
Twenty cases were treated in this study and showed a significant reduction of the viral
carriage at D6-post inclusion compared to controls, and much lower average carrying duration
than reported of untreated patients in the literature. Azithromycin added to
hydroxychloroquine was significantly more efficient for virus elimination.
Conclusion
Despite its small sample size our survey shows that hydroxychloroquine treatment is
significantly associated with viral load reduction/disappearance in COVID-19 patients and its
effect is reinforced by azithromycin.
https://drive.google.com/file/d/186Bel9RqfsmEx55FDum4xY_IlWSHnGbj/view
E: pise o tom uz aj nature:
https://www.nature.com/articles/s41421-020-0156-0?fbclid=IwAR2W52OwVd3zDO_29XwIRRf4y2WdmOumVKXupOgOh9mZ48hZgg52dhHSWJc
+ este doplnim ze v cinskych guidelines chlorochinin + azitromycin neodporucali pre potencovane riziko predlzenia QT intervalu (hydroxychlorochinin som nenasiel ale aj tu je to riziko navzajom potencovane)
March to March 16th, to receive 600mg of hydroxychloroquine daily and their viral load in
nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical
presentation, azithromycin was added to the treatment. Untreated patients from another center
and cases refusing the protocol were included as negative controls. Presence and absence of
virus at Day6-post inclusion was considered the end point.
Results
Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight
had lower respiratory tract infection symptoms.
Twenty cases were treated in this study and showed a significant reduction of the viral
carriage at D6-post inclusion compared to controls, and much lower average carrying duration
than reported of untreated patients in the literature. Azithromycin added to
hydroxychloroquine was significantly more efficient for virus elimination.
Conclusion
Despite its small sample size our survey shows that hydroxychloroquine treatment is
significantly associated with viral load reduction/disappearance in COVID-19 patients and its
effect is reinforced by azithromycin.
https://drive.google.com/file/d/186Bel9RqfsmEx55FDum4xY_IlWSHnGbj/view
E: pise o tom uz aj nature:
https://www.nature.com/articles/s41421-020-0156-0?fbclid=IwAR2W52OwVd3zDO_29XwIRRf4y2WdmOumVKXupOgOh9mZ48hZgg52dhHSWJc
+ este doplnim ze v cinskych guidelines chlorochinin + azitromycin neodporucali pre potencovane riziko predlzenia QT intervalu (hydroxychlorochinin som nenasiel ale aj tu je to riziko navzajom potencovane)